Kelun-Biotech to receive $35M up front & is eligible to receive $901M in development, approval & commercial milestones along with royalties. Both companies will collaborate on early clinical development plans for SKB-264 as a monothx. & in combination with Keytruda in advanced solid tumors
MSD gets an exclusive right to develop, manufacture & commercialize ADC. The collaboration will strengthen & diversifies MSD’s oncology pipeline for ADCs to treat cancer
The collaboration also combines MSD’s expertise with Kelun-Biotech’s innovation power to generate development synergy & advance the development & commercialization of the collaboration programs. MSD will exercise an option for global rights to SKB-264 (Ex- Greater China)
Ref: GlobalNewswire | Image: Kelun-Biotech
